音声バイオマーカーの世界市場：市場規模、シェア、動向分析、機会、予測 - タイプ別、適応症別、神経疾患別、エンドユーザー別、地域別（2019年～2029年）

世界の音声バイオマーカーの市場規模は、2022年に30億1,000万米ドルとなり、2029年には62億2,000万米ドルに達し、2023年～2029年の予測期間中にCAGRで11%の成長が予測されています。

世界市場は、パーキンソン病やその他の疾患の有病率の上昇、さまざまな病気を診断するための低侵襲性治療に対する需要の急増、心血管疾患や精神疾患の発生率の上昇を背景に、活況を呈しています。

当レポートでは、世界の音声バイオマーカー市場について調査し、市場の洞察、市場概要、地域別の市場分析、競合情勢、企業プロファイル等に関する情報を提供しています。

目次

第1章 調査の枠組み

第2章 エグゼクティブサマリー

第3章 世界の音声バイオマーカー市場の洞察

• 産業バリューチェーン分析
• DROC分析
  • 促進要因
    • パーキンソン病やその他の疾患の有病率の上昇
    • さまざまな病気を診断するための低侵襲性治療に対する需要の急増
    • 心血管疾患や精神疾患の発生率の上昇
  • 抑制要因
    • 音声バイオマーカーのエラーと不正確さ
    • 高い技術コスト
  • 機会
    • 音声バイオマーカーの研究調査の増加
    • 音声バイオマーカーにおける臨床試験の成功
  • 課題
• 技術の進歩/最近の開発
• 規制の枠組み
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入者の脅威
  • 代替品の脅威
  • 競合の激しさ

第4章 世界の音声バイオマーカーの市場概要

• 市場規模・予測、2019年～2029年
  • 金額別（10億米ドル）
• 市場シェア・予測
  • タイプ別
    • 周波数
    • 振れ幅
    • エラー率
    • 音声の立ち上がり・立ち下がり時間
    • 発声時間
    • 声の震え
    • ピッチ
  • 適応症別
    • うつ
    • 注意欠陥
    • 破壊的行動障害
    • その他
  • 神経疾患別
    • パーキンソン病
    • アルツハイマー病
    • ハンチントン病
    • 呼吸器・心血管障害
    • 外傷性脳損傷
  • エンドユーザー別
    • 病院・診療所
    • 学術研究機関
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ

第5章 北米の音声バイオマーカー市場

• 市場規模・予測、2019年～2029年
  • 金額別（10億米ドル）
• 市場シェア・予測
  • タイプ別
  • 適応症別
  • 神経疾患別
  • エンドユーザー別
  • 国別
    • 米国
    • カナダ

第6章 欧州の音声バイオマーカー市場

• 市場規模・予測、2019年～2029年
  • 金額別（10億米ドル）
• 市場シェア・予測
  • タイプ別
  • 適応症別
  • 神経疾患別
  • エンドユーザー別
  • 国別
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • オランダ
    • その他の欧州

第7章 アジア太平洋の音声バイオマーカー市場

• 市場規模・予測、2019年～2029年
  • 金額別（10億米ドル）
• 市場シェア・予測
  • タイプ別
  • 適応症別
  • 神経疾患別
  • エンドユーザー別
  • 国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア・ニュージーランド
    • インドネシア
    • マレーシア
    • シンガポール
    • フィリピン
    • ベトナム
    • その他のアジア太平洋

第8章 ラテンアメリカの音声バイオマーカー市場

• 市場規模・予測、2019年～2029年
  • 金額別（10億米ドル）
• 市場シェア・予測
  • タイプ別
  • 適応症別
  • 神経疾患別
  • エンドユーザー別
  • 国別
    • ブラジル
    • メキシコ
    • アルゼンチン
    • ペルー
    • コロンビア
    • その他のラテンアメリカ

第9章 中東・アフリカの音声バイオマーカー市場

• 市場規模・予測、2019年～2029年
  • 金額別（10億米ドル）
• 市場シェア・予測
  • タイプ別
  • 適応症別
  • 神経疾患別
  • エンドユーザー別
  • 国別
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • クウェート
    • 南アフリカ
    • ナイジェリア
    • アルジェリア
    • その他の中東・アフリカ

第10章 競合情勢

• 主要企業と製品リスト
• 世界の音声バイオマーカー企業の市場シェア分析、2022年
• 競合ベンチマーキング：運用パラメータ別
• 主要な戦略的開発（合併、買収、パートナーシップなど）

第11章 世界の音声バイオマーカー市場に対するCOVID-19の影響

第12章 企業プロファイル（企業概要、財務マトリックス、競合情勢、主要な人材、主要な競合、連絡先住所、戦略的展望、SWOT分析）

• Sonde Health
• Beyond Verbal
• IBM Corporation
• Cogito Corporation
• Boston Technology Corporation
• Microtest Health
• その他の有力企業

第13章 主要な戦略的推奨事項

第14章 調査手法

Global Vocal Biomarker Market Size More Than Doubles Cross USD 6.2 Billion by 2029.

Global vocal biomarker market is flourishing because of rising prevalence of Parkinson's and other diseases, a surging demand for minimally invasive treatments to diagnose different illnesses, and the increasing incidence of cardiovascular and mental disorders.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global vocal biomarker market size at USD 3.01 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global vocal biomarker market size to grow at a significant CAGR of 11% reaching a value of USD 6.22 billion by 2029. Major growth drivers for global vocal biomarker market include increasing incidence of neurological, psychological, and other speech-related diseases, including attention deficit, Parkinson's disease, depression, and cardiovascular diseases. These disorders necessitate less invasive tests for treatment, resulting in an increase in demand for vocal biomarkers. Vocal biomarkers are mainly used to detect illnesses using non-invasive speech features. Its use is based on the premise that severe illnesses have an effect on motor control and so change speech output by changing speech features. Vocal biomarkers are increasingly being employed to detect neurological disorders. Alzheimer's, schizophrenia, and Parkinson's disease typically manifest at a later stage of the disease, limiting the doctor's capacity to implement harsh measures. This allows pharmaceutical companies to create and test vocal biomarkers to aid in the early detection of such illnesses. Aside from healthcare, voice biomarkers have uses in lie detection. They are thought to be useful in defense and security organizations while questioning a criminal. Therefore, such factors are expected to fuel the expansion of overall market during period in analysis. However, errors and inaccuracy of vocal biomarkers is expected to hinder market growth.

Global Vocal Biomarker Market - Overview:

In the event of serious illnesses, early disease identification might mean the difference between a person's life and death. The development of new techniques that assist physicians and patients in diagnosing illnesses early has decreased death rates. Vocal biomarkers are one such advancement in the world of medicine. A human body's symptom or medical condition can be a biomarker. It is the pattern of speech in the case of vocal biomarkers. The vocal biomarkers market growth has been expanding steadily over the past several years and is predicted to have an extraordinary development in the years to come. Vocal biomarkers offer several benefits that increase their market demand. The requirement for early illness diagnosis, particularly from developed and developing nations, is one of the most crucial elements. Additionally, it is now among the most economical methods for illness diagnosis.

Global Vocal Biomarker Market - By Type:

By type, the global vocal biomarker market is segmented into amplitude, error rate, frequency, vocal rise or fall duration, voice tremor, pitch, and phonation time. The voice tremor segment is expected to hold the highest market share. It is a neurological condition that results in the uncontrollable movement of the vocal cords and throat muscles. The market dynamics will also be further influenced by the rising prevalence of neurological illnesses and the developing use of vocal tremors in neurological disorders.

Impact of COVID-19 on Global Vocal Biomarkers Market

The COVID-19 had a detrimental impact on the voice biomarkers industry globally. The pandemic has hampered the production and supply of voice biomarkers worldwide for various illnesses in these major economies. However, COVID-19 therapy now includes employs voice biomarkers. For instance, in December 2021, Vocalis Health developed a software program called Vocalis Check that evaluates a person's voice if they have an uncertain COVID-19 status. Due to the current worldwide pandemic, these developments are expected to significantly accelerate market growth and present possibilities for industry participants. The pandemic has led to an increase in the use of telemedicine and remote monitoring technologies, and vocal biomarkers may be able to play a role in these systems. For example, vocal biomarkers could potentially be used to assess the health status of patients remotely and to provide information to healthcare providers about changes in a patient's condition.

Competitive Landscape:

Major players operating in global vocal biomarker market include: Sonde Health, Beyond Verbal, IBM Corporation, Cogito Corporation, Boston Technology Corporation, and Microtest Health. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The report's in-depth analysis provides information about growth potential, upcoming trends, and the Global Vocal Biomarker Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Vocal Biomarker Market along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Vocal Biomarker Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Increasing Prevalence of Parkinson's Disease and Other Diseases
    • 3.2.1.2. Increasing Need for Minimally Invasive Treatments to Diagnose Different Illnesses
    • 3.2.1.3. Rising Incidence of Cardiovascular and Mental Disorders
  • 3.2.2. Restraints
    • 3.2.2.1. Errors and Inaccuracy of Vocal Biomarkers
    • 3.2.2.2. High Cost of Techniques
  • 3.2.3. Opportunities
    • 3.2.3.1. Increasing The Research Study of Vocal Biomarkers
    • 3.2.3.2. Successful Completion of Clinical Investigations of Voice Biomarker
  • 3.2.4. Challenges
• 3.3. Technology Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Vocal Biomarker Market Overview

• 4.1. Market Size & Forecast by Value, 2019-2029
  • 4.1.1. By Value (USD Billion)
• 4.2. Market Share & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Frequency
    • 4.2.1.2. Amplitude
    • 4.2.1.3. Error Rate
    • 4.2.1.4. Vocal Rise or Fall Time
    • 4.2.1.5. Phonation Time
    • 4.2.1.6. Voice Tremor
    • 4.2.1.7. Pitch
  • 4.2.2. By Indication
    • 4.2.2.1. Depression
    • 4.2.2.2. Attention Deficit
    • 4.2.2.3. Disruptive Behavior Disorders
    • 4.2.2.4. Others
  • 4.2.3. By Neurological Disorders
    • 4.2.3.1. Parkinson's Disease
    • 4.2.3.2. Alzheimer's Disease
    • 4.2.3.3. Huntington's Disease
    • 4.2.3.4. Respiratory and Cardiovascular Disorders
    • 4.2.3.5. Traumatic Brain Injury
  • 4.2.4. By End User
    • 4.2.4.1. Hospitals and Clinics
    • 4.2.4.2. Academic and Research
    • 4.2.4.3. Others
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia Pacific
    • 4.2.5.4. Latin America
    • 4.2.5.5. Middle East and Africa

5. North America Vocal Biomarker Market

• 5.1. Market Size & Forecast by Value, 2019-2029
  • 5.1.1. By Value (USD Billion)
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Indication
  • 5.2.3. By Neurological Disorders
  • 5.2.4. By End User
  • 5.2.5. By Country
    • 5.2.5.1. US
    • 5.2.5.1.1. By Type
    • 5.2.5.1.2. By Indication
    • 5.2.5.1.3. By Neurological Disorders
    • 5.2.5.1.4. By End User
    • 5.2.5.2. Canada
    • 5.2.5.2.1. By Type
    • 5.2.5.2.2. By Indication
    • 5.2.5.2.3. By Neurological Disorders
    • 5.2.5.2.4. By End User

6. Europe Vocal Biomarker Market

• 6.1. Market Size & Forecast by Value, 2019-2029
  • 6.1.1. By Value (USD Billion)
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Indication
  • 6.2.3. By Neurological Disorders
  • 6.2.4. By End User
  • 6.2.5. By Country
    • 6.2.5.1. Germany
    • 6.2.5.1.1. By Type
    • 6.2.5.1.2. By Indication
    • 6.2.5.1.3. By Neurological Disorders
    • 6.2.5.1.4. By End User
    • 6.2.5.2. UK
    • 6.2.5.2.1. By Type
    • 6.2.5.2.2. By Indication
    • 6.2.5.2.3. By Neurological Disorders
    • 6.2.5.2.4. By End User
    • 6.2.5.3. Italy
    • 6.2.5.3.1. By Type
    • 6.2.5.3.2. By Indication
    • 6.2.5.3.3. By Neurological Disorders
    • 6.2.5.3.4. By End User
    • 6.2.5.4. France
    • 6.2.5.4.1. By Type
    • 6.2.5.4.2. By Indication
    • 6.2.5.4.3. By Neurological Disorders
    • 6.2.5.4.4. By End User
    • 6.2.5.5. Spain
    • 6.2.5.5.1. By Type
    • 6.2.5.5.2. By Indication
    • 6.2.5.5.3. By Neurological Disorders
    • 6.2.5.5.4. By End User
    • 6.2.5.6. The Netherlands
    • 6.2.5.6.1. By Type
    • 6.2.5.6.2. By Indication
    • 6.2.5.6.3. By Neurological Disorders
    • 6.2.5.6.4. By End User
    • 6.2.5.7. Rest of Europe
    • 6.2.5.7.1. By Type
    • 6.2.5.7.2. By Indication
    • 6.2.5.7.3. By Neurological Disorders
    • 6.2.5.7.4. By End User

7. Asia-Pacific Vocal Biomarker Market

• 7.1. Market Size & Forecast by Value, 2019-2029
  • 7.1.1. By Value (USD Billion)
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Indication
  • 7.2.3. By Neurological Disorders
  • 7.2.4. By End User
  • 7.2.5. By Country
    • 7.2.5.1. China
    • 7.2.5.1.1. By Type
    • 7.2.5.1.2. By Indication
    • 7.2.5.1.3. By Neurological Disorders
    • 7.2.5.1.4. By End User
    • 7.2.5.2. India
    • 7.2.5.2.1. By Type
    • 7.2.5.2.2. By Indication
    • 7.2.5.2.3. By Neurological Disorders
    • 7.2.5.2.4. By End User
    • 7.2.5.3. Japan
    • 7.2.5.3.1. By Type
    • 7.2.5.3.2. By Indication
    • 7.2.5.3.3. By Neurological Disorders
    • 7.2.5.3.4. By End User
    • 7.2.5.4. South Korea
    • 7.2.5.4.1. By Type
    • 7.2.5.4.2. By Indication
    • 7.2.5.4.3. By Neurological Disorders
    • 7.2.5.4.4. By End User
    • 7.2.5.5. Australia & New Zealand
    • 7.2.5.5.1. By Type
    • 7.2.5.5.2. By Indication
    • 7.2.5.5.3. By Neurological Disorders
    • 7.2.5.5.4. By End User
    • 7.2.5.6. Indonesia
    • 7.2.5.6.1. By Type
    • 7.2.5.6.2. By Indication
    • 7.2.5.6.3. By Neurological Disorders
    • 7.2.5.6.4. By End User
    • 7.2.5.7. Malaysia
    • 7.2.5.7.1. By Type
    • 7.2.5.7.2. By Indication
    • 7.2.5.7.3. By Neurological Disorders
    • 7.2.5.7.4. By End User
    • 7.2.5.8. Singapore
    • 7.2.5.8.1. By Type
    • 7.2.5.8.2. By Indication
    • 7.2.5.8.3. By Neurological Disorders
    • 7.2.5.8.4. By End User
    • 7.2.5.9. Philippines
    • 7.2.5.9.1. By Type
    • 7.2.5.9.2. By Indication
    • 7.2.5.9.3. By Neurological Disorders
    • 7.2.5.9.4. By End User
    • 7.2.5.10. Vietnam
    • 7.2.5.10.1. By Type
    • 7.2.5.10.2. By Indication
    • 7.2.5.10.3. By Neurological Disorders
    • 7.2.5.10.4. By End User
    • 7.2.5.11. Rest of Asia Pacific
    • 7.2.5.11.1. By Type
    • 7.2.5.11.2. By Indication
    • 7.2.5.11.3. By Neurological Disorders
    • 7.2.5.11.4. By End User

8. Latin America Vocal Biomarker Market

• 8.1. Market Size & Forecast by Value, 2019-2029
  • 8.1.1. By Value (USD Billion)
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Indication
  • 8.2.3. By Neurological Disorders
  • 8.2.4. By End User
  • 8.2.5. By Country
    • 8.2.5.1. Brazil
    • 8.2.5.1.1. By Type
    • 8.2.5.1.2. By Indication
    • 8.2.5.1.3. By Neurological Disorders
    • 8.2.5.1.4. By End User
    • 8.2.5.2. Mexico
    • 8.2.5.2.1. By Type
    • 8.2.5.2.2. By Indication
    • 8.2.5.2.3. By Neurological Disorders
    • 8.2.5.2.4. By End User
    • 8.2.5.3. Argentina
    • 8.2.5.3.1. By Type
    • 8.2.5.3.2. By Indication
    • 8.2.5.3.3. By Neurological Disorders
    • 8.2.5.3.4. By End User
    • 8.2.5.4. Peru
    • 8.2.5.4.1. By Type
    • 8.2.5.4.2. By Indication
    • 8.2.5.4.3. By Neurological Disorders
    • 8.2.5.4.4. By End User
    • 8.2.5.5. Colombia
    • 8.2.5.5.1. By Type
    • 8.2.5.5.2. By Indication
    • 8.2.5.5.3. By Neurological Disorders
    • 8.2.5.5.4. By End User
    • 8.2.5.6. Rest of LATAM
    • 8.2.5.6.1. By Type
    • 8.2.5.6.2. By Indication
    • 8.2.5.6.3. By Neurological Disorders
    • 8.2.5.6.4. By End User

9. Middle East & Africa Vocal Biomarker Market

• 9.1. Market Size & Forecast by Value, 2019-2029
  • 9.1.1. By Value (USD Billion)
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Indication
  • 9.2.3. By Neurological Disorders
  • 9.2.4. By End User
  • 9.2.5. By Country
    • 9.2.5.1. Saudi Arabia
    • 9.2.5.1.1. By Type
    • 9.2.5.1.2. By Indication
    • 9.2.5.1.3. By Neurological Disorders
    • 9.2.5.1.4. By End User
    • 9.2.5.2. UAE
    • 9.2.5.2.1. By Type
    • 9.2.5.2.2. By Indication
    • 9.2.5.2.3. By Neurological Disorders
    • 9.2.5.2.4. By End User
    • 9.2.5.3. Qatar
    • 9.2.5.3.1. By Type
    • 9.2.5.3.2. By Indication
    • 9.2.5.3.3. By Neurological Disorders
    • 9.2.5.3.4. By End User
    • 9.2.5.4. Kuwait
    • 9.2.5.4.1. By Type
    • 9.2.5.4.2. By Indication
    • 9.2.5.4.3. By Neurological Disorders
    • 9.2.5.4.4. By End User
    • 9.2.5.5. South Africa
    • 9.2.5.5.1. By Type
    • 9.2.5.5.2. By Indication
    • 9.2.5.5.3. By Neurological Disorders
    • 9.2.5.5.4. By End User
    • 9.2.5.6. Nigeria
    • 9.2.5.6.1. By Type
    • 9.2.5.6.2. By Indication
    • 9.2.5.6.3. By Neurological Disorders
    • 9.2.5.6.4. By End User
    • 9.2.5.7. Algeria
    • 9.2.5.7.1. By Type
    • 9.2.5.7.2. By Indication
    • 9.2.5.7.3. By Neurological Disorders
    • 9.2.5.7.4. By End User
    • 9.2.5.8. Rest of MEA
    • 9.2.5.8.1. By Type
    • 9.2.5.8.2. By Indication
    • 9.2.5.8.3. By Neurological Disorders
    • 9.2.5.8.4. By End User

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Vocal Biomarker Company Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, and others)

11. Impact of Covid-19 on Global Vocal Biomarker Market

12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

• 12.1. Sonde Health
• 12.2. Beyond Verbal
• 12.3. IBM Corporation
• 12.4. Cogito Corporation
• 12.5. Boston Technology Corporation
• 12.6. Microtest Health
• 12.7. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumptions & Limitations